CH602117A5 - - Google Patents

Info

Publication number
CH602117A5
CH602117A5 CH890773A CH890773A CH602117A5 CH 602117 A5 CH602117 A5 CH 602117A5 CH 890773 A CH890773 A CH 890773A CH 890773 A CH890773 A CH 890773A CH 602117 A5 CH602117 A5 CH 602117A5
Authority
CH
Switzerland
Application number
CH890773A
Inventor
Pierre Jolles
Daniele Migliore-Samour
Original Assignee
Anvar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7222208A external-priority patent/FR2189021A1/fr
Priority claimed from FR7316130A external-priority patent/FR2227862A1/fr
Application filed by Anvar filed Critical Anvar
Publication of CH602117A5 publication Critical patent/CH602117A5/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • A61K2039/55594Adjuvants of undefined constitution from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CH890773A 1972-06-20 1973-06-19 CH602117A5 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7222208A FR2189021A1 (en) 1972-06-20 1972-06-20 Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues
FR7316130A FR2227862A1 (en) 1973-05-04 1973-05-04 Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues

Publications (1)

Publication Number Publication Date
CH602117A5 true CH602117A5 (ru) 1978-07-31

Family

ID=26217170

Family Applications (2)

Application Number Title Priority Date Filing Date
CH890773A CH602117A5 (ru) 1972-06-20 1973-06-19
CH1284476A CH592452A5 (ru) 1972-06-20 1973-06-19

Family Applications After (1)

Application Number Title Priority Date Filing Date
CH1284476A CH592452A5 (ru) 1972-06-20 1973-06-19

Country Status (10)

Country Link
US (1) US3956481A (ru)
JP (1) JPS4954590A (ru)
CA (1) CA1006836A (ru)
CH (2) CH602117A5 (ru)
DE (1) DE2331144A1 (ru)
GB (1) GB1439847A (ru)
HU (1) HU172600B (ru)
IL (1) IL42545A (ru)
NL (1) NL7308450A (ru)
SE (1) SE7604289L (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2320107A1 (fr) * 1975-08-05 1977-03-04 Anvar Nouveaux adjuvants immunologiques, procede pour leur obtention et compositions les contenant
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
JPS5846363Y2 (ja) * 1978-10-30 1983-10-21 三洋電機株式会社 太陽熱集熱器
FR2444464A1 (fr) * 1978-12-19 1980-07-18 Fabre Sa Pierre Proteoglycanes bacteriens purifies, procede pour leur preparation et vaccin les contenant
JPS568320A (en) * 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
FI75578C (fi) * 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
JPS5632490A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
JPS5632489A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
EP0026746B1 (de) * 1979-10-02 1985-04-10 Ciba-Geigy Ag Kombinationspräparate zur Anwendung in einem Verfahren zur Steigerung der Wirkung von Antibiotika, antibiotische Präparate mit gesteigerter Wirksamkeit und Verfahren zu deren Herstellung
FR2490495A1 (fr) * 1980-09-19 1982-03-26 Roussel Uclaf Nouvelles glycoproteines hydrosolubles immunostimulantes extraites de klebsiella pneumoniae, leur procede d'obtention, leur application a titre de medicaments et les compositions les renfermant
FR2490496A1 (fr) * 1980-09-19 1982-03-26 Roussel Uclaf Nouvelles glycoproteines immunostimulantes extraites de klebsiella pneumoniae, leur procede d'obtention, leur application a titre de medicaments et les compositions les renfermant
EP0056560A1 (de) * 1981-01-19 1982-07-28 Ciba-Geigy Ag Antibiotische Präparate mit gesteigerter Wirksamkeit, Verfahren zu deren Herstellung und Verfahren zur Steigerung der antibiotischen Wirkung von Antibiotika
US4503048A (en) * 1982-06-30 1985-03-05 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
US4505903A (en) * 1982-06-30 1985-03-19 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
US4504473A (en) * 1982-06-30 1985-03-12 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism
US4613504A (en) * 1983-09-23 1986-09-23 Ribi Immunochem Research, Inc. Pyridine-soluble extracts of microorganisms
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
ATE179333T1 (de) * 1993-01-29 1999-05-15 Vetrepharm Inc Immunotherapeutische zubereitung
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
JP2001519785A (ja) * 1997-04-02 2001-10-23 バイオニケ ライフ サイエンシーズ インコーポレイテッド 局所的障害および創傷の治療のための細菌細胞壁抽出物の使用
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US20040247622A1 (en) * 1999-06-02 2004-12-09 Genesis Research And Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using Mycobacterium vaccae
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
KR101096577B1 (ko) * 2010-03-09 2011-12-21 백태현 항산균 세포벽골격의 제조 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3529057A (en) * 1964-08-14 1970-09-15 Takeda Chemical Industries Ltd Purified periodic acid-oxidized mucopeptide of mycobacteria cell walls constituting a vaccine enhancing nonspecific host resistance against pathogenic bacterial infections

Also Published As

Publication number Publication date
SE7604289L (sv) 1976-04-12
CH592452A5 (ru) 1977-10-31
US3956481A (en) 1976-05-11
IL42545A0 (en) 1973-08-29
CA1006836A (en) 1977-03-15
DE2331144A1 (de) 1974-01-10
JPS4954590A (ru) 1974-05-27
NL7308450A (ru) 1973-12-27
IL42545A (en) 1977-05-31
GB1439847A (en) 1976-06-16
HU172600B (en) 1977-11-28

Similar Documents

Publication Publication Date Title
FR2189020B1 (ru)
CH593329A5 (ru)
CH572102A5 (ru)
CH1626173A4 (ru)
CH1668773A4 (ru)
CH322372A4 (ru)
CH545715A (ru)
CH545741A (ru)
CH546010A (ru)
CH555674A4 (ru)
CH561428A5 (ru)
CH561786A5 (ru)
CH569167A5 (ru)
CH570064A5 (ru)
CH570176A5 (ru)
CH570330A5 (ru)
CH570503A5 (ru)
CH571764A5 (ru)
CH591524A5 (ru)
CH572429A5 (ru)
CH572651A5 (ru)
CH572682A5 (ru)
CH573333A5 (ru)
CH573743A5 (ru)
CH574076A5 (ru)

Legal Events

Date Code Title Description
PL Patent ceased